Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
CRANBURY, N.J., May 09, 2017 -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that Pankaj Mohan, Ph.D., Chairman and Chief Executive Officer of Oncobiologics, will participate and present at the World Biosimilar Congress 2017 taking place May 23 – 24, 2017.
Event: The World Biosimilar Congress 2017
Presentation Date: May 23-24, 2017
Location: Hilton San Diego Resort and Spa, San Diego, CA
Dr. Mohan will present on “Production efficiency: Streamlining both the development and manufacturing process,” on May 23rd at 3:20 p.m. On the same day, Dr. Mohan will also participate in a panel discussion on Intellectual Property at 5:00 p.m. On May 24th at noon, he will moderate a roundtable discussion of industry executives on “Achieving required data for regulatory and commercial approvals.”
World Biosimilar Congress 2017
To learn more about the World Biosimilar Congress and to register for the conference please visit http://www.terrapinn.com/conference/biosimilar-congress-usa/index.stm
About Oncobiologics, Inc. and its BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from an in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com
CONTACTS: Oncobiologics: Lawrence A. Kenyon Chief Financial Officer [email protected] Media & Investors: Alex Fudukidis Russo Partners, LLC [email protected]
